DEP Enrollment Update, page-30

It certainly makes one wonder just when proof of concept will be finally achieved. Surely it would have to be soon as in this CY. The thing is with each new patient recruited, the longer we may have to wait as that patient is observed going through treatment cycles, disease stabilisation, progression or otherwise.

This open label trial just can’t afford to somehow roll into another calendar year. Starpharma have recruited a lot more patients than they planned and it’s gone longer than planned. I guess that could be good or bad.

As a side note, someone mentioned a few weeks ago to be cautious of relying too much on ‘individual case studies’ that Starpharma highlight, as these type of events in any type of treatment regime can sometimes be a little random. I would tend to agree with that.

The current number of recruited patients versus planned number of recruitment patients are below:

DEP docetaxel - 49 / ~ 40
DEP cabazitaxel - 42 / ~ 35
DEP Irinotecan - 53 / ~ 40-45